Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$47.33 USD
+1.41 (3.07%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $47.33 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Income Statements
Fiscal Year end for Protagonist Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 60 | 27 | 27 | 29 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 60 | 27 | 27 | 29 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 154 | 158 | 153 | 93 | 81 |
Income After Depreciation & Amortization | -94 | -131 | -126 | -65 | -81 |
Non-Operating Income | 15 | 4 | 0 | 0 | 3 |
Interest Expense | 0 | 0 | 0 | 1 | 0 |
Pretax Income | -79 | -127 | -126 | -65 | -78 |
Income Taxes | 0 | 0 | 0 | 1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -79 | -127 | -126 | -66 | -77 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -79 | -127 | -126 | -66 | -77 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -95 | -129 | -121 | -62 | -79 |
Depreciation & Amortization (Cash Flow) | -1 | 3 | 5 | 3 | 2 |
Income After Depreciation & Amortization | -94 | -131 | -126 | -65 | -81 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 56.76 | 49.04 | 46.32 | 34.40 | 25.89 |
Diluted EPS Before Non-Recurring Items | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Diluted Net EPS (GAAP) | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Fiscal Year end for Protagonist Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4.17 | 254.95 | 60.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 4.17 | 254.95 | 60.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 42.96 | 48.64 | 36.95 | 38.32 | 42.35 |
Income After SG&A, R&D, and Dept/Amort Expenses | -38.79 | 206.31 | 23.05 | -38.32 | -42.35 |
Non-Operating Income | 7.50 | 4.36 | 4.29 | 4.22 | 3.89 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -31.29 | 210.67 | 27.34 | -34.11 | -38.46 |
Income Taxes | -0.68 | 3.33 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -30.62 | 207.34 | 27.34 | -34.11 | -38.46 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -30.62 | 207.34 | 27.34 | -34.11 | -38.46 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 61.31 | 63.60 | 61.80 | 59.18 | 56.78 |
Diluted EPS Before Non-Recurring Items | -0.50 | 3.26 | 0.44 | -0.58 | -0.68 |
Diluted Net EPS (GAAP) | -0.50 | 3.26 | 0.54 | -0.58 | -0.68 |